Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 15/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | L3MBTL3 | Q96JM7 | 16/20 | 0.46 |
| ▸ | MBTD1 | Q05BQ5 | 5/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | INSR | P06213 | 1/20 | 0.44 |
| ▸ | IGF1R | P08069 | 1/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.44 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.44 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.43 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3511329 | 0.85 | ALK (0.62) | NTRK1AURKAINSRIGF1RAURKB | |
| SCHEMBL589233 | 0.82 | HRH3 (0.46) | NTRK1AURKAINSRIGF1RAURKB | |
| SCHEMBL589234 | 0.82 | HRH3 (0.46) | NTRK1AURKAINSRIGF1RAURKB | |
| SCHEMBL590429 | 0.82 | HRH3 (0.46) | NTRK1AURKAINSRIGF1RAURKB | |
| SCHEMBL23493380 | 0.79 | ALK (0.43) | NTRK1AURKAINSRIGF1RAURKB | |
| SCHEMBL23493377 | 0.79 | ALK (0.43) | NTRK1AURKAINSRIGF1RAURKB | |
| SCHEMBL589582 | 0.79 | SFRP1 (0.42) | L3MBTL1KDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL15866428 | 0.77 | L3MBTL1 (0.46) | L3MBTL1KDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL589227 | 0.77 | ALK (0.71) | NTRK1AURKAINSRIGF1RAURKB | |
| SCHEMBL589182 | 0.77 | INSR (0.63) | NTRK1AURKAINSRIGF1RAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2120932-A1 | INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | Nerviano Medical Sciences S.r.l. (IT) | 2009-11-25 | — | — | EP | claimed |
| WO-2008074749-A9 | INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | NERVIANO MEDICAL SCIENCES SRL (IT) | 2009-05-07 | — | — | WO | claimed |
| WO-2008074749-A1 | INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2008-06-26 | — | — | WO | claimed |
| EP-3107541-B1 | COMPOUNDS FOR TREATING PATIENTS WITH ROS1 MUTANT CANCER CELLS | IGNYTA INC (US) | 2020-12-23 | — | — | EP | disclosed |
| US-10682348-B2 | Molecules for administration to ROS1 mutant cancer cells | IGNYTA, INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-10561651-B2 | Methods for treating neuroblastoma | IGNYTA, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20190282564-A1 | MOLECULES FOR ADMINISTRATION TO ROS1 MUTANT CANCER CELLS | IGNYTA, INC. | 2019-09-19 | — | — | US | disclosed |
| US-10231965-B2 | Molecules for administration to ROS1 mutant cancer cells | IGNYTA, INC. (US) | 2019-03-19 | — | — | US | disclosed |
| US-20180333412-A1 | METHODS FOR TREATING NEUROBLASTOMA | IGNYTA, INC. (US) | 2018-11-22 | — | — | US | disclosed |
| US-20170007599-A1 | METHODS FOR TREATING NEUROBLASTOMA | IGNYTA, INC. | 2017-01-12 | — | — | US | disclosed |
| EP-3107541-A1 | COMPOUNDS FOR TREATING PATIENTS WITH ROS1 MUTANT CANCER CELLS | Ignyta, Inc. (US) | 2016-12-28 | — | — | EP | disclosed |
| US-8114865-B2 | Indazole derivatives as kinase inhibitors for the treatment of cancer | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-02-14 | — | — | US | disclosed |
| US-20100197665-A1 | INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-08-05 | — | — | US | disclosed |
| US-20100197665-A1 | INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-08-05 | — | — | US | disclosed |
| US-20100197665-A1 | INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-08-05 | — | — | US | disclosed |
| EP-2120932-A1 | INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | Nerviano Medical Sciences S.r.l. (IT) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008074749-A9 | INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | NERVIANO MEDICAL SCIENCES SRL (IT) | 2009-05-07 | — | — | WO | disclosed |
| WO-2008074749-A9 | INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | NERVIANO MEDICAL SCIENCES SRL (IT) | 2009-05-07 | — | — | WO | disclosed |
| WO-2008074749-A1 | INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008074749-A1 | INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170007599-A1 | METHODS FOR TREATING NEUROBLASTOMA | NEK2, CSNK1G3, AHNAK | L3MBTL1 2757/4885KDM4E 1306/4885MEN1 625/4885 |
| US-20100197665-A1 | INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | MAP3K5, MAP3K19, MAP3K3 | L3MBTL1 2658/4885KDM4E 832/4885MEN1 3368/4885 |
| US-10561651-B2 | Methods for treating neuroblastoma | UBTF, CABLES1, WEE2 | L3MBTL1 1965/4885KDM4E 1646/4885MEN1 1498/4885 |
| US-10682348-B2 | Molecules for administration to ROS1 mutant cancer cells | ROS1, KRAS, NOX1 | L3MBTL1 1421/4885KDM4E 3298/4885MEN1 3153/4885 |
| US-10231965-B2 | Molecules for administration to ROS1 mutant cancer cells | ROS1, KRAS, NOX1 | L3MBTL1 1421/4885KDM4E 3298/4885MEN1 3153/4885 |
| US-20190282564-A1 | MOLECULES FOR ADMINISTRATION TO ROS1 MUTANT CANCER CELLS | ROS1, KRAS, NOX1 | L3MBTL1 1421/4885KDM4E 3298/4885MEN1 3153/4885 |
| US-20180333412-A1 | METHODS FOR TREATING NEUROBLASTOMA | UBTF, CABLES1, WEE2 | L3MBTL1 1965/4885KDM4E 1646/4885MEN1 1498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.